• Explore /
  • Poster
  • / Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer.

Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer.

Abstract Poster

Authors

Davide Melisi

Davide Melisi

Digestive Molecular Clinical Oncology, University of Verona, Verona, Italy

Davide Melisi , Susan C. Guba , Maria Karasarides , Valerie Andre

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Clinical Trial Registration Number

NCT02734160

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract TPS501)

DOI

10.1200/JCO.2017.35.4_suppl.TPS501

Abstract #

TPS501

Poster Bd #

N19

Abstract Disclosures

Similar Posters

First Author: Davide Melisi

First Author: David A. Reardon

First Author: Erkut Hasan Borazanci

First Author: Lillian L. Siu